Pharming Group N V (PHAR) Return on Assets ROA from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, Average High and Low, Fundamental Ratios from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Pharming Group N v   (NASDAQ: PHAR)


Pharming Group N V 's ROA from the fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Pharming Group N V 's ROA in the fourth quarter of 2025?
Pharming Group N v achieved a return on average assets (ROA) of 0.51 % in its fourth quarter of 2025, this is above PHAR's average return on assets of 0.5%.
Pharming Group N V assets over the 12 months ending in its fourth quarter of 2025 are valued at $500 million

ROA has improved compared to -2.38% in the third quarter of 2025, due to net income growth.

However, within the Healthcare sector 234 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 2770.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Total Assets Change 1.68 % 25 % 25 % 25 % -9.25 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million 3 -12 -12 -12 -12
Return On Assets (TTM) 0.51 % -2.38 % -2.5 % -2.64 % -2.8 %
PHAR's Total Ranking # 2770 # # # # 3392
Total Assets (TTM) in million 500 500 500 500 492
Seq. Total Assets Change 0 % 0 % 0 % 1.68 % 22.94 %
Seq. Net Income Change - - - - -

PHAR's 5 Years Annual ROA >> Back to PHAR Management Effectiveness >> Compare PHAR ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 81
Sector # 235
Overall # 2751

Return On Assets Statistics
High Average Low
4.03 %
0.5 %
-2.96 %
(Dec 31 2021)   (Dec 31 2024)





Financial Statements
Pharming Group N V 's Assets $ 500 million PHAR's Balance sheet
Pharming Group N V 's Income $ 3 million Quarterly PHAR's Income Statement
PHAR's Income by Division See PHAR's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 34.43 % -9.25 % -1.68 % 4.72 % -5 %
Total Assets in million 661 492 542 551 526
Y / Y Net Income Change - - - -14.52 % -57.62 %
Net Income in million 3 -12 -11 14 16
Annual Return On Assets 0.38 % -2.41 % -1.95 % 2.48 % 3.04 %

PHAR's 5 Years Annual ROA >> Back to PHAR Management Effectiveness >> Compare PHAR ROA to its Competitors



Comment on PHAR's ROA in the fiscal year ending 2025
In the fiscal year 2025 ROA improved to 0.38 % compared to prior year, due to annual net income growth of % to $2.54 million, while value of Pharming Group N V 's overall assets grew just by 34.43 % to $661.04 million, compared to $661.04 a year before.


More Return On Assets Ratios
PHAR's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
PHAR's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for PHAR's Competitors
Subscribers only: Roa for Pharming Group N V 's Suppliers
Subscribers only: Return On Assets for PHAR's Customers

You may also want to know
PHAR's Roi PHAR's Inventory Turnover Ratio PHAR's Growth Rates PHAR's Dividend Comparisons
PHAR's Profitability Ratios PHAR's Asset Turnover Ratio PHAR's Dividend Growth
PHAR's Roe PHAR's Valuation Ratios PHAR's Financial Strength Ratios PHAR's Dividend Payout Ratio



Companies with similar Return On Assets at Dec 31 2025, within Healthcare Sector ROA
Surgery Partners Inc   1.24 %
Artivion Inc   1.16 %
Mannkind Corporation  1.11 %
Castle Biosciences Inc   0.98 %
Envista Holdings Corporation  0.84 %
Innovage Holding Corp   0.63 %
Pharming Group N v   0.51 %
Pacira Biosciences inc   0.49 %
Radnet Inc   0.48 %
Lifestance Health Group Inc   0.45 %
Bausch Health Companies Inc   0.45 %
Perspective Therapeutics Inc   0.26 %
Warby Parker Inc   0.23 %
Crescent Biopharma Inc   0.11 %

Date modified: 2026-07-07T12:47:48+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.